FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2025049237> ?p ?o ?g. }

• W2025049237 endingPage "78" @default.
• W2025049237 startingPage "73" @default.
• W2025049237 abstract "GERD prevalence continues to rise in contrast to peptic ulcer disease. The spectrum contains reflux esophagitis and so-called 'endoscopy-negative GERD' or 'non-erosive GERD' (NERD) or S-GERD and patients with 'normal' overall 24-h esophageal acidification but with a high 'symptom-index'. The majority of reflux patients will not need endoscopy initially. Prompt referral for endoscopy is indicated only if the patient has atypical symptoms or alarm symptoms such as dysphagia, anemia, weight loss, severe abdominal pain, or pain that does not respond to acid neutralization or suppression, or develops symptoms after the age of 50 years. Antireflux therapy consist of raising the head of the bed, maintaining normal weight, and avoidance of foods and drugs that precipitate symptoms, together with antacids or over-the-counter H(2) receptor antagonists (H(2)RAs). If symptoms persist after these simple measures or if antacids or H(2)RAs are needed quite often, then a more formal first-line treatment should be started. Many experts feel that a stepdown approach instead of a stepup approach is clinically and economically a more appropriate way of installing such first-line therapy. Physicians increasingly consider prescribing a (low- or standard dose) once-a-day proton pump inhibitor (PPI) as firstline therapy. If symptoms recur after 4-week trial or are in sufficiently relieved, then the patient should be referred for endoscopy. Endoscopy may reveal no abnormalities (NERD) or evidence of reflux-induced damage. Treatment of endoscopy-negative reflux disease should be directed towards rapid relief of symptoms and then maintenance of relief using minimum effective therapy. Responses to PPIs are somewhat lower in endoscopy-negative patients compared to esophagitis. Some form of long-term therapy is needed in the majority of patients. 'On demand' PPI therapy to control reflux symptoms is a new and attractive option. The goal of treatment of GERD should be to relieve symptoms and to heal lesions. Symptom severity and much less endoscopic abnormalities, drives the therapy. When symptoms are mild or intermittent and when esophagitis is absent or minimal, standard dose PPI is usually reinstituted. If there is moderate or severe esophagitis or if symptoms are particularly troublesome, then the patient should start again with standard-dose PPI therapy once a day, but not uncommonly a b.i.d. dosage maybe necessary. Once a dose of the acid suppressant that relieves symptoms is found, this dose should be maintained for a period of 3 months. After this time, an attempt should be made to reduce the dose. A plan should be formulated for long-term treatment." @default.
• W2025049237 created "2016-06-24" @default.
• W2025049237 creator A5073597941 @default.
• W2025049237 date "2002-05-31" @default.
• W2025049237 modified "2023-09-27" @default.
• W2025049237 title "Treatment of mild and severe cases of GERD" @default.
• W2025049237 cites W1969557642 @default.
• W2025049237 cites W1977227339 @default.
• W2025049237 cites W1979584324 @default.
• W2025049237 cites W1984465775 @default.
• W2025049237 cites W1986108044 @default.
• W2025049237 cites W1986194415 @default.
• W2025049237 cites W1988220078 @default.
• W2025049237 cites W1993356863 @default.
• W2025049237 cites W1993571494 @default.
• W2025049237 cites W1996559022 @default.
• W2025049237 cites W1998128185 @default.
• W2025049237 cites W1998138296 @default.
• W2025049237 cites W2009165618 @default.
• W2025049237 cites W2017410957 @default.
• W2025049237 cites W2019203561 @default.
• W2025049237 cites W2024697584 @default.
• W2025049237 cites W2024939791 @default.
• W2025049237 cites W2032487234 @default.
• W2025049237 cites W2033028341 @default.
• W2025049237 cites W2038762359 @default.
• W2025049237 cites W2042158053 @default.
• W2025049237 cites W2068000031 @default.
• W2025049237 cites W2068723528 @default.
• W2025049237 cites W2068859916 @default.
• W2025049237 cites W2070479837 @default.
• W2025049237 cites W2081256702 @default.
• W2025049237 cites W2084303393 @default.
• W2025049237 cites W2126528782 @default.
• W2025049237 cites W2171125008 @default.
• W2025049237 cites W2411212554 @default.
• W2025049237 cites W4238092795 @default.
• W2025049237 cites W4238774668 @default.
• W2025049237 cites W4249481007 @default.
• W2025049237 doi "https://doi.org/10.1046/j.1365-2036.16.s4.11.x" @default.
• W2025049237 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12047264" @default.
• W2025049237 hasPublicationYear "2002" @default.
• W2025049237 type Work @default.
• W2025049237 sameAs 2025049237 @default.
• W2025049237 citedByCount "28" @default.
• W2025049237 countsByYear W20250492372012 @default.
• W2025049237 countsByYear W20250492372014 @default.
• W2025049237 countsByYear W20250492372015 @default.
• W2025049237 countsByYear W20250492372016 @default.
• W2025049237 countsByYear W20250492372017 @default.
• W2025049237 countsByYear W20250492372021 @default.
• W2025049237 crossrefType "journal-article" @default.
• W2025049237 hasAuthorship W2025049237A5073597941 @default.
• W2025049237 hasBestOaLocation W20250492371 @default.
• W2025049237 hasConcept C126322002 @default.
• W2025049237 hasConcept C141071460 @default.
• W2025049237 hasConcept C2776462128 @default.
• W2025049237 hasConcept C2777014526 @default.
• W2025049237 hasConcept C2777683962 @default.
• W2025049237 hasConcept C2778451229 @default.
• W2025049237 hasConcept C2779134260 @default.
• W2025049237 hasConcept C2779920096 @default.
• W2025049237 hasConcept C2780596822 @default.
• W2025049237 hasConcept C2780955771 @default.
• W2025049237 hasConcept C2781025758 @default.
• W2025049237 hasConcept C43270747 @default.
• W2025049237 hasConcept C71924100 @default.
• W2025049237 hasConcept C90924648 @default.
• W2025049237 hasConceptScore W2025049237C126322002 @default.
• W2025049237 hasConceptScore W2025049237C141071460 @default.
• W2025049237 hasConceptScore W2025049237C2776462128 @default.
• W2025049237 hasConceptScore W2025049237C2777014526 @default.
• W2025049237 hasConceptScore W2025049237C2777683962 @default.
• W2025049237 hasConceptScore W2025049237C2778451229 @default.
• W2025049237 hasConceptScore W2025049237C2779134260 @default.
• W2025049237 hasConceptScore W2025049237C2779920096 @default.
• W2025049237 hasConceptScore W2025049237C2780596822 @default.
• W2025049237 hasConceptScore W2025049237C2780955771 @default.
• W2025049237 hasConceptScore W2025049237C2781025758 @default.
• W2025049237 hasConceptScore W2025049237C43270747 @default.
• W2025049237 hasConceptScore W2025049237C71924100 @default.
• W2025049237 hasConceptScore W2025049237C90924648 @default.
• W2025049237 hasIssue "s4" @default.
• W2025049237 hasLocation W20250492371 @default.
• W2025049237 hasLocation W20250492372 @default.
• W2025049237 hasOpenAccess W2025049237 @default.
• W2025049237 hasPrimaryLocation W20250492371 @default.
• W2025049237 hasRelatedWork W1597918229 @default.
• W2025049237 hasRelatedWork W2038062995 @default.
• W2025049237 hasRelatedWork W2347286114 @default.
• W2025049237 hasRelatedWork W2351629079 @default.
• W2025049237 hasRelatedWork W2461403891 @default.
• W2025049237 hasRelatedWork W2476548940 @default.
• W2025049237 hasRelatedWork W3141124350 @default.
• W2025049237 hasRelatedWork W4285154846 @default.
• W2025049237 hasRelatedWork W46859026 @default.
• W2025049237 hasRelatedWork W2586336379 @default.
• W2025049237 hasVolume "16" @default.

• next